Carriage Services Appoints Kian Granmayeh as Chief 7-03-2023, 05:02

Quantexa Reaches Centaur Status, Surpassing $100 Million ARR 29-10-2024, 07:01

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26